查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1886899

mRNA疫苗市场规模、占有率、成长及全球产业分析：依类型、应用和地区划分的洞察，以及2024年至2032年的预测

mRNA Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 160 Pages | 商品交期: 请询问到货日

价格

mRNA疫苗市场成长驱动因子

随着药物创新和传染病防治策略的变革，全球mRNA疫苗市场持续快速发展。 2024年，该市场规模预计将达到89.1亿美元，主要得益于基因技术的进步、强大的研发管线以及新冠疫情后持续的需求。到2025年，随着新冠疫苗需求的正常化，预计市场规模将调整至60.1亿美元，但长期前景仍乐观。到2032年，mRNA疫苗市场预计将显着成长，达到204.3亿美元，主要得益于其在传染病、肿瘤、自体免疫疾病和个人化医疗等领域应用的持续拓展。

截至2024年，北美将以35.13%的市占率引领全球市场。这得归功于北美强大的医疗基础设施、较高的疫苗接种率、众多大型生物製药企业的存在以及政府的大量投资。 Moderna、辉瑞-BioNTech和CureVac等领导企业正透过持续的研发投入和拓展下一代疫苗产品组合来增强其竞争优势。

市场动态

市场推动因素

推动市场成长的关键因素是加大研发投入，致力于将mRNA疫苗的应用范围扩展到新冠肺炎以外的其他疾病。以mRNA为基础的新冠肺炎疫苗的成功加速了全球对开发类似疫苗的兴趣，这些疫苗可以预防流感、呼吸道合胞病毒（RSV）、爱滋病以及各种新兴传染病。 Moderna和BioNTech等公司正在加大投资；例如，Moderna 已宣布计划在 2024 年至 2028 年间投资 250 亿美元用于研发。此类投资可确保强大的产品线和持续创新。

此外，各组织正利用人工智慧加速临床开发。辉瑞的 AI 驱动智慧数据查询 (SDQ) 系统在疫​​情期间加速了临床数据审查，凸显了 AI 驱动型疫苗开发的潜力。

市场限制因子

监理挑战持续限制市场成长。儘管疫情期间审批速度加快，但其他疾病的 mRNA 疫苗仍面临漫长的验证流程，尤其是在美国 FDA 的研究性新药 (IND) 和生物製品许可申请 (BLA) 流程中。标准化生产方案、确保冷链需求以及维持 mRNA 稳定性等复杂因素进一步增加了监管压力。

市场机会

mRNA 疫苗应用范围的扩大带来了巨大的机会。除了传染病领域，mRNA技术正被探索用于癌症疫苗、自体免疫疾病和罕见遗传疾病的研发。在强大的研发管线和不断增加的全球临床试验的推动下，非新冠肺炎领域的mRNA疫苗预计将在未来十年加速发展。世界卫生组织（世卫组织）提出的2024年推动禽流感（H5N1）先进mRNA疫苗研发的倡议，进一步增强了未来的发展机会。

市场挑战

大众对疫苗接种的犹豫仍然是一项重大挑战，尤其是在资讯不实、认知度低和医疗资源匮乏的地区。智慧财产权纠纷，例如Moderna和Arbutus之间的纠纷，也影响市场竞争格局。此外，大规模mRNA疫苗生产的复杂性（需要低温储存和先进的脂质奈米颗粒递送系统）也为新兴市场带来了生产方面的挑战。

市场趋势

技术进步

主要趋势包括自扩增mRNA的开发、改良的脂质奈米颗粒（LNP）递送系统、人工智慧赋能的临床研究。这些创新正在提高疫苗效力、减少接种频率并降低生产成本。美国FDA和欧洲药品管理局（EMA）等监管机构的持续支持也在加速疫苗的研发週期。

策略联盟

整个产业的合作关係正在增加。 BioNTech与CEPI和Mpox在2023年合作开发疟疾疫苗，反映了全球对新兴传染病的策略关注。

依类型划分的洞见

依类型划分

2024年，在全美疫苗接种运动的推动下，新冠疫苗细分市场引领市场。同时，非新冠疫苗市场正在快速扩张，呼吸道合胞病毒（RSV）、流感、狂犬病和癌症疫苗等研发管线正逐渐展现出临床应用价值。

依适应症划分

2024年，由于需要加强免疫接种以及变异株的出现，新冠病毒感染病例占最大。包括Moderna公司获得FDA批准的mRESVIA（2024年）在内的呼吸道合胞病毒疫苗展现出强劲的成长潜力。

依通路划分

由于疫情期间大规模疫苗接种基础设施的建设，医院和零售药局在2024年成为市场的主要推动力。政府机构也透过大规模疫苗接种计画做出了重大贡献。

区域展望

北美市场在2024年将占主导地位，市场规模达31.3亿美元，这得益于其强大的研发能力、健全的监管框架和大规模的生产能力。

欧洲则位居第二，这得益于其有利的疫苗接种政策和较高的疫苗接种率。

由于传染病日益流行和生物技术投资不断增长，预计亚太地区将在未来几年内实现最快增长。

其他地区，市场持续受益于新的生产基地，例如 BioNTech 在卢安达的 mRNA 生产设施（2023 年）。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场推动因素
  • 市场阻碍因素
  • 市场机遇
  • 市场趋势

第四章：关键洞察

  • 主要公司新产品发布
  • 主要公司产品线分析
  • mRNA 疫苗市场的技术进步
  • 主要疾病的发生率/盛行率（2024）
  • 关键产业趋势（併购、合作及其他）

第五章 全球mRNA疫苗市场分析、洞察与预测（2019-2032）

  • 市场分析、洞察与预测 - 依类型划分
    • 新冠病毒疫苗
    • 非新冠病毒疫苗
  • 市场分析、洞察与预测 - 依适应症划分
    • 新冠病毒感染
    • 呼吸道合胞病毒（RSV）感染
    • 其他
  • 市场分析、洞察与预测 - 依分销管道划分
    • 医院和零售药局
    • 政府供应商
    • 其他
  • 市场分析、洞察与预测 - 依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 其他

第六章 北美mRNA疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲mRNA疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 其他地区欧洲

第八章 亚太地区mRNA疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章 其他mRNA疫苗市场分析、洞察与预测（2019-2032）

第十章 竞争分析

  • 全球市占率分析（2024）
  • 公司简介
  • Moderna Inc.
  • BioNTech
  • CureVac SE
  • GSK plc
  • 赛诺菲
  • 辉瑞公司
  • 金诺生物製药股份有限公司
  • 华生生技有限公司
  • Arcturus Therapeutics
Product Code: FBI113546

Growth Factors of mRNA vaccines Market

The global mRNA vaccines market continues to evolve rapidly as pharmaceutical innovations and infectious disease management strategies transform global vaccine development. The market was valued at USD 8.91 billion in 2024, supported by advances in genetic technologies, strong R&D pipelines, and sustained demand following the COVID-19 pandemic. In 2025, the market size is expected to adjust to USD 6.01 billion, reflecting normalization in COVID-19 vaccine demand; however, long-term prospects remain promising. By 2032, the mRNA vaccines market is projected to grow significantly, reaching USD 20.43 billion, driven by increasing applications across infectious diseases, oncology, autoimmune disorders, and personalized medicine.

North America dominated the global market in 2024 with 35.13% share, backed by strong healthcare infrastructure, high vaccine adoption, major biopharmaceutical manufacturers, and substantial government investment. Key players such as Moderna, Pfizer-BioNTech, and CureVac have strengthened their competitive positioning through continual R&D investments and the expansion of next-generation vaccine portfolios.

Market Dynamics

Market Drivers

A primary growth driver is the increase in research and development activities focused on expanding mRNA vaccine applications beyond COVID-19. The success of mRNA-based COVID-19 vaccines accelerated global interest in developing similar vaccines for influenza, RSV, HIV, and various emerging infectious diseases. Companies such as Moderna and BioNTech are expanding their investment commitments-Moderna, for instance, announced plans to invest USD 25 billion in R&D between 2024 and 2028. Such investments ensure robust pipelines and continued innovation.

Moreover, organizations are leveraging artificial intelligence for faster clinical development. Pfizer's adoption of the AI-driven Smart Data Query (SDQ) system accelerated clinical data review during the pandemic, highlighting the potential of AI-enabled vaccine development.

Market Restraints

Regulatory challenges continue to restrain market growth. Despite accelerated approvals during the pandemic, mRNA vaccines for other diseases face lengthy validation processes, particularly in the U.S. FDA's IND and BLA pathways. Complexities in standardizing manufacturing protocols, ensuring cold-chain requirements, and maintaining mRNA stability add further regulatory pressure.

Market Opportunities

Expanding applications of mRNA vaccines present substantial opportunities. Beyond infectious diseases, mRNA technology is being explored for cancer vaccines, autoimmune diseases, and rare genetic disorders. With strong pipeline momentum and increasing clinical trials globally, the non-COVID-19 segment is expected to accelerate over the next decade. The World Health Organization's 2024 initiative to develop an advanced mRNA vaccine for avian influenza (H5N1) further strengthens future opportunities.

Market Challenges

Public vaccine hesitancy remains a major challenge, particularly in regions with misinformation, low awareness, or weaker healthcare access. Intellectual property conflicts-such as disputes involving Moderna and Arbutus-also impact competitive dynamics. Additionally, the complexity of large-scale mRNA vaccine production, involving sensitive cold storage and advanced lipid nanoparticle delivery systems, poses manufacturing challenges for emerging markets.

Market Trends

Technological Advancements

Key trends include the development of self-amplifying mRNA, improved lipid nanoparticle (LNP) delivery systems, and AI-guided clinical research. These innovations enhance vaccine efficacy, reduce dosing frequency, and lower production costs. Continuous regulatory support from agencies such as the U.S. FDA and EMA is also contributing to faster vaccine innovation cycles.

Strategic Collaborations

Collaborations are rising across the sector. BioNTech's partnership with CEPI in 2023 to develop vaccines for Mpox and malaria reflects strategic global interest in emerging infectious diseases.

Segmentation Insights

By Type:

The COVID-19 vaccines segment dominated in 2024 due to global vaccination campaigns. Meanwhile, the non-COVID-19 vaccine segment is expanding rapidly with RSV, influenza, rabies, and cancer vaccine pipelines growing in clinical significance.

By Indication:

COVID-19 infection held the largest share in 2024 owing to booster requirements and evolving variants. RSV vaccines, including Moderna's FDA-approved mRESVIA (2024), show strong growth potential.

By Distribution Channel:

Hospital and retail pharmacies led the market in 2024 due to large-scale vaccination infrastructure established during the pandemic. Government suppliers also contributed significantly through mass immunization programs.

Regional Outlook

North America dominated with USD 3.13 billion in 2024 due to robust research capabilities, strong regulatory frameworks, and large-scale manufacturing.

Europe ranked second, supported by favorable vaccination policies and high acceptance rates.

Asia Pacific is expected to see the fastest future growth, driven by rising infectious disease prevalence and expanding biotech investments.

Rest of the World continues to benefit from new manufacturing facilities, such as BioNTech's mRNA plant in Rwanda (2023).

Conclusion

The global mRNA vaccines market is on a dynamic growth trajectory from USD 8.91 billion (2024) to USD 20.43 billion (2032). With expanding applications, technological breakthroughs, and rising global investment, mRNA vaccines are positioned to remain a transformative force in modern medicine.

Segmentation By Type

  • COVID-19 Vaccines
  • Non-COVID-19 Vaccines

By Indication

  • COVID-19 Infection
  • Respiratory Syncytial Virus (RSV) Infection
  • Others

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Type, Indication, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Indication, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Indication, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Rest of the World (By Type, Indication, and Distribution Channel)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. New Product Launches, By Key Players
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Technological Advancements in the mRNA Vaccines Market
  • 4.4. Incidence/Prevalence of Key Diseases, 2024
  • 4.5. Key Industry Developments (Mergers, Acquisitions, and Partnerships, etc.)

5. Global mRNA Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. COVID-19 Vaccines
    • 5.1.2. Non-COVID-19 Vaccines
  • 5.2. Market Analysis, Insights and Forecast - By Indication
    • 5.2.1. COVID-19 Infection
    • 5.2.2. Respiratory syncytial virus (RSV) Infection
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital & Retail Pharmacies
    • 5.3.2. Government Suppliers
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America mRNA Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. COVID-19 Vaccines
    • 6.1.2. Non-COVID-19 Vaccines
  • 6.2. Market Analysis, Insights and Forecast - By Indication
    • 6.2.1. COVID-19 Infection
    • 6.2.2. Respiratory syncytial virus (RSV) Infection
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital & Retail Pharmacies
    • 6.3.2. Government Suppliers
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe mRNA Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. COVID-19 Vaccines
    • 7.1.2. Non-COVID-19 Vaccines
  • 7.2. Market Analysis, Insights and Forecast - By Indication
    • 7.2.1. COVID-19 Infection
    • 7.2.2. Respiratory syncytial virus (RSV) Infection
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital & Retail Pharmacies
    • 7.3.2. Government Suppliers
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific mRNA Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. COVID-19 Vaccines
    • 8.1.2. Non-COVID-19 Vaccines
  • 8.2. Market Analysis, Insights and Forecast - By Indication
    • 8.2.1. COVID-19 Infection
    • 8.2.2. Respiratory syncytial virus (RSV) Infection
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital & Retail Pharmacies
    • 8.3.2. Government Suppliers
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Rest of the World mRNA Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. COVID-19 Vaccines
    • 9.1.2. Non-COVID-19 Vaccines
  • 9.2. Market Analysis, Insights and Forecast - By Indication
    • 9.2.1. COVID-19 Infection
    • 9.2.2. Respiratory syncytial virus (RSV) Infection
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital & Retail Pharmacies
    • 9.3.2. Government Suppliers
    • 9.3.3. Others

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2024)
  • 10.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 10.2.1. Moderna Inc.
      • 10.2.1.1. Overview
      • 10.2.1.2. Products & services
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. BioNTech
      • 10.2.2.1. Overview
      • 10.2.2.2. Products & services
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. CureVac SE
      • 10.2.3.1. Overview
      • 10.2.3.2. Products & services
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. GSK plc
      • 10.2.4.1. Overview
      • 10.2.4.2. Products & services
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. Sanofi
      • 10.2.5.1. Overview
      • 10.2.5.2. Products & services
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. Pfizer Inc.
      • 10.2.6.1. Overview
      • 10.2.6.2. Products & services
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)
    • 10.2.7. Gennova Biopharmaceuticals Limited
      • 10.2.7.1. Overview
      • 10.2.7.2. Products & services
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. Financials (Based on Availability)
    • 10.2.8. Walvax Biotechnology Co., Ltd.
      • 10.2.8.1. Overview
      • 10.2.8.2. Products & services
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. Financials (Based on Availability)
    • 10.2.9. Arcturus Therapeutics
      • 10.2.9.1. Overview
      • 10.2.9.2. Products & services
      • 10.2.9.3. SWOT Analysis
      • 10.2.9.4. Recent Developments
      • 10.2.9.5. Strategies
      • 10.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global mRNA Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 2: Global mRNA Vaccines Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 3: Global mRNA Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 4: Global mRNA Vaccines Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 5: North America mRNA Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 6: North America mRNA Vaccines Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 7: North America mRNA Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 8: North America mRNA Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 9: Europe mRNA Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 10: Europe mRNA Vaccines Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 11: Europe mRNA Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 12: Europe mRNA Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Asia Pacific mRNA Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 14: Asia Pacific mRNA Vaccines Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 15: Asia Pacific mRNA Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 16: Asia Pacific mRNA Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 17: Rest of the World mRNA Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 18: Rest of the World mRNA Vaccines Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 19: Rest of the World mRNA Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032a

List of Figures

  • Figure 1: Global mRNA Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global mRNA Vaccines Market Value Share (%), by Type, 2024 & 2032
  • Figure 3: Global mRNA Vaccines Market Value Share (%), by Indication, 2024 & 2032
  • Figure 4: Global mRNA Vaccines Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 5: Global mRNA Vaccines Market Value Share (%), by Region, 2024 & 2032
  • Figure 6: North America mRNA Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 7: North America mRNA Vaccines Market Value Share (%), by Type, 2024
  • Figure 8: North America mRNA Vaccines Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 9: North America mRNA Vaccines Market Value Share (%), by Indication, 2024
  • Figure 10: North America mRNA Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 11: North America mRNA Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 12: North America mRNA Vaccines Market Value (USD billion), By Country, 2024 & 2032
  • Figure 13: North America mRNA Vaccines Market Value Share (%), By Country, 2024
  • Figure 14: Europe mRNA Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 15: Europe mRNA Vaccines Market Value Share (%), by Type, 2024
  • Figure 16: Europe mRNA Vaccines Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 17: Europe mRNA Vaccines Market Value Share (%), by Indication, 2024
  • Figure 18: Europe mRNA Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 19: Europe mRNA Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 20: Europe mRNA Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 21: Europe mRNA Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 22: Asia Pacific mRNA Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 23: Asia Pacific mRNA Vaccines Market Value Share (%), by Type, 2024
  • Figure 24: Asia Pacific mRNA Vaccines Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 25: Asia Pacific mRNA Vaccines Market Value Share (%), by Indication, 2024
  • Figure 26: Asia Pacific mRNA Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 27: Asia Pacific mRNA Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 28: Asia Pacific mRNA Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 29: Asia Pacific mRNA Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 30: Rest of the World mRNA Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 31: Rest of the World mRNA Vaccines Market Value Share (%), by Type, 2024
  • Figure 32: Rest of the World mRNA Vaccines Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 33: Rest of the World mRNA Vaccines Market Value Share (%), by Indication, 2024
  • Figure 34: Rest of the World mRNA Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 35: Rest of the World mRNA Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 36: Global mRNA Vaccines Market Share (%), By Company, 2024